Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Japan’s health ministry formally approved Novavax’s COVID-19 vaccine, a fourth foreign-developed tool to combat the infections

The Independent UK

Scientists developing 'blockbuster' heart attack cure using Covid vaccine tech

Researchers from King's College London are working on regenerating damaged hearts in the hope of developing a cure for heart attacks - with human trials set to begin within two years.

Daily Record

Two long COVID Patients Recover After Pfizer's Therapy; Side Effects, Safety Needs To Be Assessed: Reuters

Reuters reported that two patients found relief from long COVID after taking Pfizer Inc's (NYSE:PFE) antiviral Paxlovid, including a researcher who tested it on herself. Long COVID is estimated to affect up to 30% of people infected with the coronavirus. It can last for months. More than 200 symptoms have been associated with the…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Heart attack cure discovered thanks to new tech - which works like Covid vaccine

Researchers from King's College London have found a way to stimulate the creation of healthy heart cells - which can then be delivered to the muscle using the same technology used with the Moderna and Pfizer Covid vaccines

Daily Mirror

Covid vaccine boosters - why healthy people aren't being offered them yet

Should you get in line for a second booster ASAP?

Wales Online

California Democrats are delaying their vaccine plans. Here's why

SACRAMENTO, Calif. — California Democrats were moving toward requiring COVID-19 vaccines for students and keeping them from opting out of shots with personal belief exemptions.

Tribune News Service

Pfizer Stock, Raytheon Lead 5 Stocks Near Buy Points

Pfizer and Raytheon are among 5 stocks near buy points that offer protection from geopolitics and aggressive rate-hikes.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Will AbbVie And These Two Other Drug Stocks Reinvigorate — Or Incinerate?

A bullish first-quarter report could reinvigorate AbbVie stock, an analyst said Thursday after a C-suite setback this week.

Investors Business Daily

New Valneva covid vaccine and its links to Bristol explained

The UK has become the first major country to approve Valneva's vaccine against covid-19

Bristol Post

Pfizer/BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Aged 5-11 Years

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced results from a Phase 2/3 trial of a 10 µg booster (third) dose of COVID-19 vaccine in children aged 5-11 years.

Benzinga

Pfizer says coronavirus booster dose increased immune response in children ages 5 to 11

If federal regulators verify the claims, children over the age of five could gain access to boosters.

Axios

Pfizer to seek COVID booster for healthy 5- to 11-year-olds

Pfizer wants to expand its COVID-19 booster shots to healthy 5- to 11-year-olds

The Independent UK

Pfizer/BioNTech say booster dose increases protection vs Omicron in kids aged 5-11

A third dose of the COVID-19 vaccine from Pfizer Inc and BioNTech produced significant protection against the Omicron variant of the coronavirus in healthy children ages 5 to 11, the companies said on Thursday.

Reuters

Commentary: Is a second booster for COVID-19 the right choice for you?

The Food and Drug Administration and the Centers for Disease Control and Prevention recently authorized a second booster shot of the Pfizer/BioNTech and Moderna COVID-19 vaccines for those age 50 and older. The recommendation follows a study out of Israel recently published in The New England Journal of Medicine.

Chicago Tribune

Get all your
news in one place.

100’s of premium titles.
One news app.

Wales Online

Healthy young people don’t need a fourth Covid jab, says virus expert

Welsh immunologist says we'd be better off vaccinating the rest of the world to protect against new variants than giving young, healthy people a fourth shot

Daily Mirror

Woman claims rare reaction to Covid jab saw her 'age 20 years in three days'

Michelle Flower, from Sheffield, says she had a rare adverse reaction to having a Pfizer Covid booster in January that led to her "ageing 20 years in just three days"

Wales Online

Woman claims rare reaction to booster jab left her with hives and cuts ‘ageing her 20 years in three days’

The woman is adamant she is not an anti-vaxxer and is keen to make people aware of alleged risks

The Philadelphia Inquirer

Marcus Hayes: Half-vaxxed Matisse Thybulle is a bad (and badly informed) Sixers teammate

PHILADELPHIA — The Sixers’ biggest problem used to be, they had a guy who wouldn’t take a shot.

Get all your
news in one place.

100’s of premium titles.
One news app.

Manchester Evening News

Woman claims her Covid booster jab has 'aged her 20 years in three days' - but still wants people to get jabbed

On the NHS website, it states that serious allergic reactions to the Covid-19 vaccines are very rare and usually occur within minutes

The Philadelphia Inquirer

Sixers coach Doc Rivers encouraged Matisse Thybulle to get vaccinated but continued ‘to support the kid’

PHILADELPHIA — Doc Rivers has known all season that 76ers starting wing Matisse Thybulle was not vaccinated against COVID-19. Rivers added he “encouraged [Thybulle] all year” to receive the required shot(s).

Investors Business Daily

Myovant Sciences Collapses As FDA Holdup Snags Its Blockbuster Potential

The future looked cloudy for Myovant Sciences and Pfizer's partnered endometriosis treatment on Tuesday, leading MYOV stock to collapse.

Benzinga

What's Going On With Myovant Sciences Stock Today?

Myovant Sciences Ltd (NYSE: MYOV) shares are trading significantly lower Tuesday after the company and Pfizer Inc (NYSE: PFE) announced an update on the Supplemental New Drug Application for MYFEMBREE for the manag

Benzinga

The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

The Conversation

COVID vaccines: why second boosters are being offered to vulnerable people in the UK – but not young and healthy people yet

Until recently, the UK government limited a fourth dose of the COVID vaccine to people with severely weakened immune systems over the age of 16.

ABC News

Pfizer offers $100m to buy Brisbane company behind smartphone app that diagnoses COVID-19

Pfizer offers $100 million to buy a ResApp, a company that has invented a smartphone app it says can diagnose COVID-19 by listening to someone cough.

1 … 56 57 58 59

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Centers for Disease Control and Prevention

283 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.